期刊文献+

乙型肝炎相关原发性肝癌患者的生存分析 被引量:6

Survival analysis on patients with hepatitis B related primary liver cancer
原文传递
导出
摘要 目的探讨影响乙型肝炎相关原发性肝癌患者1年预后的独立指标并建立危险指数模型,评价该模型对于判断此类患者1年内死亡风险的价值。方法收集首都医科大学附属北京地坛医院2008年9月~2012年7月所收治的434例乙型肝炎相关原发性肝癌患者的临床资料,随机选出257例(60%)组成建模组,其余177例(40%)组成验证组。观察影响患者1年预后的危险因素,运用Cox风险比例回归模型进行单因素和多因素生存分析。根据多因素分析的结果建立危险指数模型,并评价其判断此类患者1年内死亡风险的价值。结果 Cox回归模型分析结果显示,影响患者1年预后的独立指标共有6个,分别为中性粒细胞/淋巴细胞比值(NLR)、终末期肝病模型(MELD)评分、中性粒细胞计数(NC)、红细胞(RBC)计数、低密度脂蛋白胆固醇(LDL-C)和载脂蛋白A1(ApoA1)。根据以上指标建立的危险指数模型:PI=3+0.062×NLR+0.137×MELD+0.114×NC-0.365×RBC+0.639×(LDL-C)-1.377×(ApoA1),界值为3.58。建模组受试者工作特征(ROC)曲线下面积高达0.857,准确性为78.6%。验证ROC曲线下面积为0.858,准确性为78.5%。结论本研究建立的危险指数模型判断乙型肝炎相关原发性肝癌1年内死亡风险的准确性高,对于临床医生判断患者转归情况,选用更合理的治疗方法具有一定的参考价值。 Objective To establish a risk index model by statistical analysis on independent prognostic factors which affect the prognosis of patients with hepatitis B related primary liver cancer in one year, and its value would be evaluated on predicting the mortality risk of these patients. Methods Total of 434 patients with hepatitis B related primary liver cancer in our hospital during September 2008 to July 2012 were enrolled. They were randomly divided into training group (257 cases, 60% ) and validation group ( 177 cases, 40% ). First, some prognostic risk factors were obtained through clinical observation. Then, the univariate and multivariate survival analysis were performed using Cox regression model. Based on the multivariate analysis results, a risk index model was established and its effects on predicting the one-year mortality risk of those patients were evaluated. Results Cox regression analysis showed that there were six independent factors affecting the prognosis of patients with hepatitis B related primary liver cancer in one year, which were neutrophil-to-lymphoeyte ratio (NLR), MELD score, neutrophil count (NC) , red blood cell (RBC) count, low density lipoprotein cholesterol (LDL-C) and apolipoprotein A1 (Apo A1 ), respectively. The risk index model established according to the above factors was expressed as PI = 3 + 0.062 x NLR + 0.137 x MELD + 0.114 x NC-0.365 x RBC + 0.639 x (LDL-C) - 1.377 x (Apo A1) , and the cut-off value was 3.58. In the training group, the area under the receiver operating characteristic curve (AUROC) and the accuracy were 0. 857 and 78. 6% , respectively. While in the validation group, the AUROC and the accuracy were 0. 858 and 78.5% , respectively. Conclusions The risk index model was established in this study to predict the mortality risk of hepatitis B related primary liver cancer, with a high accuracy. It could help doctors to evaluate the patients' conditions and choose reasonable treatment methods.
出处 《中华实验和临床感染病杂志(电子版)》 CAS 2013年第1期55-60,共6页 Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
基金 北京市科技计划课题(No.Z111107056811044) 北京市中医药科技发展基金科技提升专项(No.KJTS2011-05) 首都医学发展基金(No.SF-2007-Ⅲ-03)
关键词 原发性肝癌 肝炎 乙型 生存分析 COX模型 Primary liver cancer Hepatitis B Survival analysis Cox model
  • 相关文献

参考文献17

  • 1Bosch FX, Ribes J, Clries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis,2005,9(2) : 191-211.
  • 2原发性肝癌的I临床诊断与分期标准.中国抗癌协会肝癌专业委员会第八届全国肝癌学术会议.广州.2001,9.
  • 3贾继东,李兰娟.慢性乙型肝炎防治指南(2010年版)[J].中华肝脏病杂志,2011,19(1):13-24. 被引量:3203
  • 4文洁,朱德增.中晚期原发性肝癌患者的危险因素分析[J].中国现代医学杂志,2011,21(7):841-845. 被引量:12
  • 5张俊勇,刘吉勇,张福奎,王宝恩,贾继东.终末期肝病模型对原发性肝癌患者预后的判断价值[J].中华消化杂志,2006,26(4):271-272. 被引量:4
  • 6Pinato DJ, Sharma R. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. Transl Res,2012,160 ( 2 ) : 146-152.
  • 7Siegel I, Liu TL, Gleicher N. The red-cell immune system. Lancet, 1981,2(8246) :556-559.
  • 8Emlen W, Burdick G, Carl V, et al. Binding of model immune complexes to erythrocyte CR1 facilitates immune complex uptake by U937 cells. J Immunol, 1989,142 ( 12 ) :4366-4371.
  • 9Shau H, Gupta RK, Golub SH. Identification of a natural killer enhancing factor (NKEF) from human erythroid cell. Cell immunol, 1993,147(1) :1-11.
  • 10彭慎安,张建军.150例肝病患者红细胞6项指标检测结果分析[J].中西医结合肝病杂志,2000,10(5):52-53. 被引量:1

二级参考文献35

共引文献3232

同被引文献61

  • 1杨帆,张琪,陈规划.肝癌细胞免疫治疗进展[J].外科研究与新技术,2013,2(4):262-266. 被引量:4
  • 2Sheng, Qin-Song,Lang, Ren,He, Qiang,Yang, Yong-Jiu,Zhao, De-Fang,Chen, Da-Zhi.Indocyanine green clearance test and model for end-stage liver disease score of patients with liver cirrhosis[J].Hepatobiliary & Pancreatic Diseases International,2009,8(1):46-49. 被引量:36
  • 3刘鹏飞,刘荣华,徐荷,吴孟超.原发性肝癌术后预防性TACE的意义(附433例病例随访)[J].中华肝胆外科杂志,2005,11(2):81-82. 被引量:52
  • 4Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
  • 5Jemal A, Siegel R, Xu J, et al. Cancer statistcs, 2010[J]. CA Cancer J Clin, 2010, 60(5):277-300.
  • 6Bober J, Samek E Surgery of the tumors of the liver[J]. Bratial Lek Listy, 2001, 103(11):403-407.
  • 7Krejci T, Skricka T, R zicka M, et al. Surgical liver resection in multimodal therapy of hepatic malignat affections: a 4-year study[J]. Arch Oncol, 2002, 10:1-5. doi: 10.2298/AOO0201001K.
  • 8Pinato D J, Sharma R. An inflammation-based prognostic index predicts survival advantage after transarterial chemocmbolization in hepatocellular carcinoma[J]. Transl Res, 2012, 160(2): 146-152.
  • 9Sumic S, Kuromatsu R, Okuda K, ct al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors[J].Ann Surg Oncol, 2008, 15(5):1375- 1382.
  • 10Ardiles V, Smchez Clarii R, Mazza OM, et al. Prognostic factors after resection of hepatocellular carcinoma in the non-cirrhotic liver: presentation of 51 cases[J]. Cir Esp, 2010, 87(3): 148-154.

引证文献6

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部